Inhibrx Biosciences is releasing Phase 2 primary endpoint data for INBRX-106 on September 8, four days after announcing the webcast, a pace that signals the company wants little air between announcement and disclosure. The data come from the randomized, controlled portion of the HexAgon study, which pits INBRX-106 plus pembrolizumab against pembrolizumab alone in 68 patients with treatment-naive, PD-L1 positive (CPS ≥ 20) metastatic or unresectable recurrent head and neck squamous cell carcinoma, 33 in the combination arm and 35 on monotherapy.
The mechanistic premise is what makes this readout worth watching. OX40 agonism has a long history of underwhelming results with conventional bivalent antibodies, which lack the receptor clustering density T-cells appear to need for durable activation. INBRX-106 is hexavalent, meaning six OX40-binding domains per molecule rather than two, built on Inhibrx’s single-domain antibody platform. Whether that structural difference translates into measurable clinical benefit over pembrolizumab, FDA-approved in this setting since June 2019, is the question the primary endpoint answers.
Context matters for reading whatever number comes out Tuesday. The 68-patient randomized cohort is sized to detect a signal, not to power a registration claim, so a positive result would raise the immediate question of what Phase 3 design Inhibrx would pursue. A null result carries different weight: it would not just close the HNSCC program but would pressure the broader OX40 agonist hypothesis at a time when several companies have already struggled to show that costimulatory receptor activation adds meaningfully to checkpoint inhibition in solid tumors. Inhibrx Biosciences itself is a leaner entity than its predecessor, having spun out from Inhibrx, Inc. after Sanofi’s $1.7 billion acquisition of the parent closed in May 2024 and took the INBRX-101 rare disease program with it, leaving INBRX-106 and ozekibart (INBRX-109) as the remaining clinical assets.
The primary endpoint result is the concrete moment: if the combination arm shows a meaningful improvement in the pre-specified endpoint over pembrolizumab monotherapy, Inhibrx has a basis for a larger trial; if it does not, the hexavalent OX40 rationale faces a serious empirical test in the most relevant patient population the company has studied.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
